These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 9492559)

  • 21. Reversible late gadolinium enhancement in a case of Takotsubo cardiomyopathy following high-dose dobutamine stress MRI.
    Bruder O; Hunold P; Jochims M; Waltering KU; Sabin GV; Barkhausen J
    Int J Cardiol; 2008 Jun; 127(1):e22-4. PubMed ID: 17467826
    [No Abstract]   [Full Text] [Related]  

  • 22. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
    Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
    Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
    Wolansky LJ; Haghighi MH; Sevdalis E; Cook SD; Sethi N; Liu J; Joseph G; Tulloch K; Cadavid D
    J Neuroimaging; 2005 Jul; 15(3):289-90. PubMed ID: 15951416
    [No Abstract]   [Full Text] [Related]  

  • 24. Images in cardiovascular medicine. Late enhancement of a left ventricular cardiac fibroma assessed with gadolinium-enhanced cardiovascular magnetic resonance.
    De Cobelli F; Esposito A; Mellone R; Papa M; Varisco T; Besana R; del Maschio A
    Circulation; 2005 Sep; 112(13):e242-3. PubMed ID: 16186429
    [No Abstract]   [Full Text] [Related]  

  • 25. Optimising the design of paramagnetic MRI contrast agents: influence of backbone substitution on the water exchange rate of Gd-DTPA derivatives.
    Laurent S; Botteman F; Vander Elst L; Muller RN
    MAGMA; 2004 Apr; 16(5):235-45. PubMed ID: 15029509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: results of phase I and phase II clinical trials.
    Tanimoto A; Kadoya M; Kawamura Y; Kuwatsuru R; Gokan T; Hirohashi S
    J Magn Reson Imaging; 2006 Apr; 23(4):499-508. PubMed ID: 16534755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [What is late gadolinium enhancement in hypertrophic cardiomyopathy?].
    Moon JC
    Rev Esp Cardiol; 2007 Jan; 60(1):1-4. PubMed ID: 17288947
    [No Abstract]   [Full Text] [Related]  

  • 28. Gold nanoparticles functionalised by Gd-complex of DTPA-bis(amide) conjugate of glutathione as an MRI contrast agent.
    Park JA; Reddy PA; Kim HK; Kim IS; Kim GC; Chang Y; Kim TJ
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6135-7. PubMed ID: 18938074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary?
    Hermann KG; Landewé RB; Braun J; van der Heijde DM
    J Rheumatol; 2005 Oct; 32(10):2056-60. PubMed ID: 16206370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast magnetic resonance imaging: principles and techniques.
    Kaiser WA
    Semin Roentgenol; 2007 Oct; 42(4):228-35. PubMed ID: 17919525
    [No Abstract]   [Full Text] [Related]  

  • 31. A horse-riding accident and haemolytic anaemia.
    Bittle CC
    Lancet; 2004 Nov 6-12; 364(9446):1728. PubMed ID: 15530636
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiac cysticercosis.
    Shogan PJ; Yasmer JF; Monson M
    AJR Am J Roentgenol; 2009 May; 192(5):W212-3. PubMed ID: 19380525
    [No Abstract]   [Full Text] [Related]  

  • 33. [Now the National Board of Health is sleeping again--or is it a question of discrimination?].
    Thomsen HS
    Ugeskr Laeger; 2011 Jun; 173(26):1899; discussion 1899. PubMed ID: 21845776
    [No Abstract]   [Full Text] [Related]  

  • 34. No drug is benign.
    Latchaw RE
    AJNR Am J Neuroradiol; 1998 Sep; 19(8):1386-7. PubMed ID: 9763364
    [No Abstract]   [Full Text] [Related]  

  • 35. Residual or Retained Gadolinium.
    Ben Salem D; Ognard J; Guiu B
    Radiology; 2016 Nov; 281(2):650-651. PubMed ID: 27755932
    [No Abstract]   [Full Text] [Related]  

  • 36. [Gadolinium-DTPA tolerance and clinical safety].
    Niendorf HP; Brasch RC
    Rontgenpraxis; 1997 Dec; 50(12):354-63. PubMed ID: 9492559
    [No Abstract]   [Full Text] [Related]  

  • 37. Gadolinium and kidney disease: are your patients at risk?
    Hollister D
    Nephrol Nurs J; 2008; 35(2):196-7. PubMed ID: 18472687
    [No Abstract]   [Full Text] [Related]  

  • 38. MR arthrography: pharmacology, efficacy and safety in clinical trials.
    Schulte-Altedorneburg G; Gebhard M; Wohlgemuth WA; Fischer W; Zentner J; Wegener R; Balzer T; Bohndorf K
    Skeletal Radiol; 2003 Jan; 32(1):1-12. PubMed ID: 12525938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
    Shellock FG; Parker JR; Pirovano G; Shen N; Venetianer C; Kirchin MA; Spinazzi A
    J Magn Reson Imaging; 2006 Dec; 24(6):1378-85. PubMed ID: 17078095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notes on "Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent".
    Runge VM
    AJR Am J Roentgenol; 2008 Jun; 190(6):1433-4. PubMed ID: 18492887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.